High. This portfolio invests in biotechnology and healthcare companies involved in genomics, a sector characterized by high research and development costs, regulatory risks, and clinical trial dependencies. While the sector has significant long-term growth potential, it is also subject to high market volatility and company-specific risks tied to scientific breakthroughs and regulatory approvals.
You are looking for exposure to companies at the forefront of healthcare innovation, particularly in the fields of genetic research, diagnostics, and advanced therapies. This portfolio is suitable for investors who are comfortable with the risks associated with the biotechnology sector and are seeking long-term growth opportunities in healthcare.
Genomics is a rapidly evolving field with the potential to revolutionize healthcare through personalized medicine, advanced diagnostics, and targeted therapies. Advances in genetic sequencing, gene editing, and molecular diagnostics are enabling more precise disease identification and treatment options, leading to improved patient outcomes.
Key factors driving this theme include declining costs of genetic sequencing, increased adoption of precision medicine, advancements in gene therapy technologies such as CRISPR, and growing investment in biotechnology research. As healthcare systems prioritize more personalized and efficient treatment approaches, companies involved in genomics research and innovation are expected to play a critical role in shaping the future of medicine.
The Genomics Portfolio offers diversified exposure to this sector by investing in companies across the genomics value chain, including genetic testing and diagnostics providers, biotechnology firms focused on gene editing and therapy, and companies developing advanced therapeutic solutions. This approach allows investors to participate in the long-term growth potential of an industry positioned at the intersection of science, technology, and healthcare innovation.
For this portfolio, we have identified the below companies:
| Company | Description |
|---|---|
| CareDx, Inc. (CDNA) | CareDx, Inc. provides genomic surveillance solutions for transplant patients, helping clinicians monitor the health of transplanted organs through non-invasive DNA testing. |
| CRISPR Therapeutics AG (CRSP) | CRISPR Therapeutics AG is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. |
| Guardant Health, Inc. (GH) | Guardant Health, Inc. specializes in precision oncology through its liquid biopsy tests, which analyze genomic data from blood samples to detect and monitor cancer. |
| Illumina, Inc. (ILMN) | Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, providing the essential tools and platforms that fuel advancements in genomic research. |
| Moderna, Inc. (MRNA) | Moderna, Inc. pioneers messenger RNA (mRNA) therapeutics and vaccines, using genetic information to instruct the body's cells to prevent or fight a wide range of diseases. |
| Natera, Inc. (NTRA) | Natera, Inc. is a specialist in cell-free DNA testing, offering a range of genomic diagnostics for reproductive health, cancer detection, and organ transplant monitoring. |
| QIAGEN N.V. (QGEN) | QIAGEN N.V. provides essential sample and assay technologies that isolate and process DNA, RNA, and proteins, enabling molecular testing and genomic research worldwide. |
| Regeneron Pharmaceuticals, Inc. (REGN) | Regeneron Pharmaceuticals, Inc. heavily invests in large-scale human genetics research to discover novel drug targets and develop innovative medicines for a wide range of diseases. |
| Twist Bioscience Corporation (TWST) | Twist Bioscience Corporation manufactures synthetic DNA on a large scale, providing foundational genetic tools for applications ranging from drug development to DNA-based data storage. |
| Veracyte, Inc. (VCYT) | Veracyte, Inc. is a genomic diagnostics company that develops advanced tests to resolve diagnostic uncertainty in cancer and other diseases, helping to guide patient care decisions. |
| Vertex Pharmaceuticals Incorporated (VRTX) | Vertex Pharmaceuticals Incorporated specializes in creating transformative medicines for serious diseases by focusing on the underlying genetic or biological causes, particularly in cystic fibrosis. |